Open Access Peer-reviewed Research Article

Considering the clarithromycin resistance prevalence among Helicobacter pylori strains isolated from patients with Gastric complication

Article Sidebar

Pathological feature
Download PDF
Submitted   May 10, 2024
Published   Mar 17, 2025
Issue    Vol 6 (2024)
DOI   10.25082/CCR.2024.01.005

Views

114

Downloads

35

Citations

PlumX Metrics

Main Article Content

Alireza Ahmadzadeh corresponding author
Department of Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Zhaleh Mohsenifar
Department of Pathology, School of Medicine, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Behzad Hatami
Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Ali Pirsalehi
Department of Internal Medicine, School of Medicine, Shahid Beheshti University of medical Sciences, Tehran, Iran
Mostafa Rezaei-Tavirani
[1] Department of lablatory Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; [2] Proteomics Research Center, Paramedical Sciences Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Objective:  Helicobacter pylori is a major cause of gastric cancer. This study aimed to determine the frequency of clarithromycin resistance and its association with point mutations in the 23S rRNA gene.
Methods: This study was conducted on 100 patients with gastric disorders who were referred to Valiasr Hospital in 2022. Two biopsy samples were obtained from each patient for pathological and microbiological examinations. Antimicrobial susceptibility testing was performed using the agar dilution method, and polymerase chain reaction (PCR) was used for molecular analysis.
Results: Among the patients, 53% (53/100) were diagnosed as H. pylori-positive. Pathological findings indicated that 54.7% (29/53) of the H. pylori-positive patients had chronic gastritis, 37.7% (20/53) had severe active gastritis, and 7.5% (4/53) had intestinal metaplasia. Clarithromycin resistance was detected in 13.2% (7/53) of the patients. The MIC50 and MIC90 values were determined to be 0.125 mg/L and 2 mg/L, respectively. PCR results revealed that the A2142G point mutation in the 23S rRNA gene was present in all clarithromycin-resistant strains.
Conclusions: Our findings indicate that the presence of the A2142G point mutation in the 23S rRNA gene may be associated with clarithromycin resistance in H. pylori strains. These results underscore the importance of routine screening for resistance genotypes to guide effective treatment strategies.

Keywords
Helicobacter pylori, gastric cancer, clarithromycin resistance, histopathological changes, minimum inhibitory concentration

Article Details

How to Cite
Ahmadzadeh, A., Mohsenifar, Z., Hatami, B., Pirsalehi, A., & Rezaei-Tavirani, M. (2025). Considering the clarithromycin resistance prevalence among Helicobacter pylori strains isolated from patients with Gastric complication. Current Cancer Reports, 6(1), 241-247. https://doi.org/10.25082/CCR.2024.01.005
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. Guo Y, Cao XS, Guo GY, et al. Effect of Helicobacter Pylori Eradication on Human Gastric Microbiota: A Systematic Review and Meta-Analysis. Frontiers in Cellular and Infection Microbiology. 2022, 12. https://doi.org/10.3389/fcimb.2022.899248
  2. Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World Journal of Clinical Cases. 2022, 10(19): 6349-6359. https://doi.org/10.12998/wjcc.v10.i19.6349
  3. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017, 153(2): 420-429. https://doi.org/10.1053/j.gastro.2017.04.022
  4. Tran V, Saad T, Tesfaye M, et al. Helicobacter pylori (H. pylori) risk factor analysis and prevalence prediction: a machine learning-based approach. BMC Infectious Diseases. 2022, 22(1). https://doi.org/10.1186/s12879-022-07625-7
  5. Massarrat S, Saberi-Firoozi M, Soleimani A, et al. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. European journal of gastroenterology & hepatology. 1995, 7(5): 427-433. https://pubmed.ncbi.nlm.nih.gov/7614105
  6. Goldberg L, Amrick TJ. Successful Eradication of Helicobacter pylori with 5-Day Concomitant Treatment. Aye TT, ed. GastroHep. 2022, 2022: 1-4. https://doi.org/10.1155/2022/1211329
  7. Leung WK, Graham DY. Clarithromycin for Helicobacter pylori infection. Expert Opinion on Pharmacotherapy. 2000, 1(3): 507-514. https://doi.org/10.1517/14656566.1.3.507
  8. Kocsmár É, Buzás GM, Szirtes I, et al. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nature Communications. 2021, 12(1). https://doi.org/10.1038/s41467-021-22557-7
  9. Hosseini RS, Rahimian G, Shafigh MH, et al. Correlation between clarithromycin resistance, virulence factors and clinical characteristics of the disease in Helicobacter pylori infected patients in Shahrekord, Southwest Iran. AMB Express. 2021, 11(1). https://doi.org/10.1186/s13568-021-01310-9
  10. Albasha AM, Elnosh MM, Osman EH, et al. Helicobacter pylori 23S rRNA gene A2142G, A2143G, T2182C, and C2195T mutations associated with clarithromycin resistance detected in Sudanese patients. BMC Microbiology. 2021, 21(1). https://doi.org/10.1186/s12866-021-02096-3
  11. Bordin D, Morozov S, Plavnik R, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022, 27(5). https://doi.org/10.1111/hel.12924
  12. Gharibi S, Falsafi T, Alebouyeh M, et al. Relationship between histopathological status of the Helicobacter pylori infected patients and proteases of H. pylori in isolates carrying diverse virulence genotypes. Microbial Pathogenesis. 2017, 110: 100-106. https://doi.org/10.1016/j.micpath.2017.06.023
  13. Kahlmeter G, Brown DFJ, Goldstein FW, et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clinical Microbiology and Infection. 2006, 12(6): 501-503. https://doi.org/10.1111/j.1469-0691.2006.01454.x
  14. Bińkowska A, Biernat MM, Łaczmański Ł, et al. Molecular Patterns of Resistance Among Helicobacter pylori Strains in South-Western Poland. Frontiers in Microbiology. 2018, 9. https://doi.org/10.3389/fmicb.2018.03154
  15. Bohr URM, Primus A, Zagoura A, et al. A Group‐Specific PCR Assay for the Detection of Helicobacteraceae in Human Gut. Helicobacter. 2002, 7(6): 378-383. https://doi.org/10.1046/j.1523-5378.2002.00113.x
  16. Kauser F, Hussain MA, Ahmed I, et al. Comparative genomics of Helicobacter pylori isolates recovered from ulcer disease patients in England. BMC Microbiology. 2005, 5(1). https://doi.org/10.1186/1471-2180-5-32
  17. Pan ZJ, Su WW, Tytgat GNJ, et al. Assessment of Clarithromycin-Resistant Helicobacter pylori among Patients in Shanghai and Guangzhou, China, by Primer-Mismatch PCR. Journal of Clinical Microbiology. 2002, 40(1): 259-261. https://doi.org/10.1128/jcm.40.1.259-261.2002
  18. Furuta T, Soya Y, Sugimoto M, et al. Modified allele-specific primer–polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. Journal of Gastroenterology and Hepatology. 2007, 22(11): 1810-1815. https://doi.org/10.1111/j.1440-1746.2007.04919.x
  19. Alexander SM, Retnakumar RJ, Chouhan D, et al. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Frontiers in Microbiology. 2021, 12. https://doi.org/10.3389/fmicb.2021.713955
  20. Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter Pylori in Iran: A Review. Middle East Journal of Digestive Diseases. 2017, 10(1): 5-17. https://doi.org/10.15171/mejdd.2017.84
  21. Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics. 2020, 9(8): 436. https://doi.org/10.3390/antibiotics9080436
  22. Yilmaz Ö. Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. World Journal of Gastroenterology. 2007, 13(5): 671. https://doi.org/10.3748/wjg.v13.i5.671
  23. Khademi F, Poursina F, Hosseini E, et al. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iranian journal of basic medical sciences. 2015, 18(1): 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366738
  24. Alavifard H, Mirzaei N, Yadegar A, et al. Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian Population: A Cross-Sectional Study. Current Microbiology. 2020, 78(1): 244-254. https://doi.org/10.1007/s00284-020-02295-7
  25. Huang X, Liu Y, Lin Z, et al. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China. Siddique MH, ed. PLOS ONE. 2021, 16(9): e0256225. https://doi.org/10.1371/journal.pone.0256225
  26. Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europein 2018 and its relationship to antibiotic consumption in the community. Gut. 2021, 70: 1815–1822. https://pubmed.ncbi.nlm.nih.gov/33837118
  27. De Francesco V, Zullo A, Fiorini G, et al. Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication. Journal of Antimicrobial Chemotherapy. 2018, 74(3): 772-774. https://doi.org/10.1093/jac/dky469
  28. Hussein RA, Al-Ouqaili MTS, Majeed YH. Detection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates of Helicobacter pylori isolates: Phenotypic and molecular methods. Saudi Journal of Biological Sciences. 2022, 29(1): 513-520. https://doi.org/10.1016/j.sjbs.2021.09.024
  29. Khashei R, Dara M, Bazargani A, et al. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. APMIS. 2016, 124(9): 787-793. https://doi.org/10.1111/apm.12567
  30. Seo SI, Do BJ, Kang JG, et al. Helicobacter pylori Eradication According to Sequencing-Based 23S Ribosomal RNA Point Mutation Associated with Clarithromycin Resistance. Journal of Clinical Medicine. 2019, 9(1): 54. https://doi.org/10.3390/jcm9010054